Skip to content

Study of Bala and Atibala ayurvedic drugs and to see the effect of its milk decoction in patients suffering from Janu sandhigatavata

A PHYTOCHEMICAL STUDY OF BALA DWAYAM SIDA CORDIFOLIA & ABUTILON INDICUM LINN AND CLINICAL EVALUATION OF ITS MOOLA CHURNA KSHEERAPAKA IN SANDHIVATA W.S.R TO JANU SANDHI

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018183
Enrollment
60
Registered
2019-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: oral medication: ksheerapaka 80 ml twice daily for both the groups for 30 days Control Intervention1: Oral medication in the form of Ksheerapaka.: Ksheerapaka of Bala( Sida cordifolia)

Sponsors

Manna Mathew
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Classical sign and symptoms of JanuSandhigatavata are Shula, Shotha, Stambha, Sparsha-asahyata, Sphutana, Akunchana PrasaranaVedana etc at the joints

Exclusion criteria

Exclusion criteria: •Patients below 45 and above 70 years of age. •Patients with other joints deformities or diseases which are not related to Sandhigatavata,such as Amavata,Vatarakta,fracture of joints ,and needs surgical care will be excluded. •Autoimmuno diseases like SLE, Anklosing Spondylitis.

Design outcomes

Primary

MeasureTime frame
Assessment will be done according to specially designed proformaTimepoint: Treatment will be given for 30 days and eventually assessed on day 15 and 30.

Secondary

MeasureTime frame
Improvement in the quality of lifeTimepoint: on 30th day

Countries

India

Contacts

Public ContactDr Varghese Jibi Thankachan

Maharashtra University of Health Sciences, Nashik

vjayu82@gmail.com8983478062

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026